Thalidomide
From Glioblastoma Treatments
Property | Information |
---|---|
Drug Name | Thalidomide |
FDA Approval | Yes (for leprosy and multiple myeloma) |
Used for | Investigational use in various cancers due to antiangiogenic and immunomodulatory properties |
Clinical Trial Phase | Ongoing optimization of thalidomide analogues |
Clinical Trial Explanation | Not specified |
Common Side Effects | Deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, teratogenicity |
OS without | Not specified |
OS with | Not specified; ongoing studies for cancer-specific outcomes |
PFS without | Not specified |
PFS with | Not specified; research focuses on enhancing therapeutic profiles while minimizing toxicity |
Usefulness Rating | 3 |
Usefulness Explanation | Not specified |
Toxicity Level | 4 |
Toxicity Explanation | Thalidomide, although it has shown promise in treating various cancers, has a high level of toxicity due to side effects such as deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, and teratogenicity (risks to a developing fetus). As such, it's rated as 4 out of 5, with 5 being the most toxic. Keep in mind that these effects may vary from person to person, so it is important to discuss the risks and benefits with your healthcare provider. |
Notes: Recent advances in thalidomide-related compounds target anticancer efficacy with reduced side effects. These developments suggest thalidomide analogues could become a promising therapeutic alternative for cancer treatment, enhancing the drug's applicability beyond its current FDA-approved uses. Continued research aims to refine these compounds to maximize benefits and minimize risks.
From Ben Williams Book: Not specified
Loading comments...